First, therapies targeting IL-21/IL-21R are under development for type 1 diabetes, rheumatoid arthritis, and psoriasis (23), and our findings suggest that therapies blocking IL-21 or IL-21 signaling may be effective as a therapeutic target for inflammatory neuropathies. Here, IL21R is linked to type 1 diabetes mellitus.